Log in to your Inderes Free account to see all free content on this page.

Skapa användarkonto

FluoGuide

34,25

SEK

−1,72 %

FLUO

First North Stockholm

Medical Equipment & Services

Health Care

7 investerare följer bolaget.

−1,72%

−13,29%

−15,01%

−29,38%

−44,04%

−53,59%

−61,34%

+359,82%

+282,03%

fluoguide.com/investor/share-information

FluoGuide är ett danskt bolag verksamma inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar mot olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.

Omsättning

-

EBIT%

-

P/E

-

Direktavkastnings- %

-

Riktkurs

-

Rekommendation

-

Uppdaterad

-

First North Stockholm

FLUO

Dagens lägsta / högsta pris

34,25 / 35,9 SEK

Börsvärde

466,49 mn SEK

Omsatt (värde)

309,94 tn SEK

Omsatt (antal)

8,9 tn

Senast publicerade videor

Introduction to FluoGuide

Finansiell kalender

Delårsrapport

27.11.2024

Årsredovisning

27.02.2025

Största ägare
Källa: Millistream Market Data AB

Ägare	Kapital	Röster
Life Science IVS	17,4 %	17,4 %
Wexotec ApS	12,2 %	12,2 %

Premium

Innehållet är endast tillgängligt för våra Premium-kunder.

Mera information

Login in to make your own estimates and see other investors estimates.

VisarAlla typer av innehåll

Pressmeddelande2024-11-19 12:43

Publication of positive phase II clinical data for FG001 in patients with head and neck cancer

Regulatoriskt pressmeddelande2024-11-12 17:23

FluoGuide A/S issue warrants to board member, CMO and CFO

Pressmeddelande2024-10-21 14:13

Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

FREE account

Stock market's most popular morning newsletter

Tillgång till analytikerkommentarer och rekommendationer

Vårt eget aktiescreeningsverktyg

PREMIUM account

Alla aktieanalyser och övrigt innehåll

Premiumverktyg (insidertransaktioner och aktiescreeningsverktyg)

Inderes modellportfölj

Skapa användarkonto

Pressmeddelande2024-10-07 11:13

FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer

Pressmeddelande2024-08-29 17:19

Redeye: Fluoguide Q2 2024 - Following the plan

Regulatoriskt pressmeddelande2024-08-29 06:55

FluoGuide A/S publishes interim report for the period January – June 2024

Regulatoriskt pressmeddelande2024-08-26 07:05

FluoGuide appoints Jens Ellrich as Chief Medical Officer

Regulatoriskt pressmeddelande2024-06-18 21:12

FluoGuide has completed a directed share issue to existing and new investors raising proceeds of SEK 60 million

Regulatoriskt pressmeddelande2024-06-18 15:31

FluoGuide intends to carry out a directed share issue of approximately SEK 60 million

Pressmeddelande2024-05-30 14:51

Redeye: Fluoguide Q1 2024 - Preparing for next steps

Regulatoriskt pressmeddelande2024-05-30 06:51

FluoGuide A/S publishes interim report for the period January – March 2024

Pressmeddelande2024-05-27 07:40

FluoGuide selects laser system for photothermal cancer therapy with FG001

Fluoguide: Wrap up from interview with CEO Morten Albrechtsen

Analytikerkommentar2024-03-21 07:30 av

Fluoguide: Wrap up from interview with CEO Morten Albrechtsen

Dive into the company's latest partnership with Intuitive Surgical and how the partnership looks like for Fluoguide.

Regulatoriskt pressmeddelande2024-03-20 13:25

Minutes from Annual General Meeting in FluoGuide A/S

HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.

Analytikerkommentar2024-03-14 08:36 av

Henrik Ekman, Philip Coombes, Claus Thestrup

HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.

After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent.

Ascelia Pharma BioPorto Curasight ExpreS2ion Biotech Holding FluoGuide NeoDynamics Pharma Equity Group Qlife Holding

Regulatoriskt pressmeddelande2024-03-13 10:17

Chief Financial Officer (CFO) Ole Larsen buys shares

Regulatoriskt pressmeddelande2024-03-12 11:12

FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company

Fluoguide: Wrap up from introduction to the company

Analytikerkommentar2024-03-05 12:18 av

Henrik Ekman, Claus Thestrup

Fluoguide: Wrap up from introduction to the company

Interview with CEO Morten Albrechtsen about the pipeline and opportunities

Regulatoriskt pressmeddelande2024-03-01 11:41

Notice of Annual General Meeting in FluoGuide A/S

Pressmeddelande2024-02-28 13:20

Redeye: Fluoguide Q4 2023 - Bright prospects